Sakata Y, Saito G, Sakata S, Oya Y, et al. Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426]. Lung Cancer 2023 Dec 29:107450. doi: 10.1016/j.lungcan.2023.107450.
PMID: 38160082